Ypsomed invests $250 million in a new U.S. manufacturing facility, enhancing local supply and creating jobs in Holly Springs, ...

In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ...

DTC programs aim to enhance patient access by offering lower prices, but require navigating complex regulatory and licensing ...

Another major pharmaceutical company is striking a deal with President Trump.

Bristol Myers Squibb (BMS) announced a definitive agreement in which BMS will acquire Orbital Therapeutics along with its ...

Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic ...

Legal challenges to the MFN order may focus on constitutional issues and the statutory authority of the HHS Secretary, ...

The deadline for DSCSA compliance is approaching. For many in the industry, this moment marks the end of a long regulatory ...

Regeneron's Libtayo gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, enhancing ...

FDA approves Jascayd, the first new treatment for idiopathic pulmonary fibrosis in over a decade, significantly reducing ...

In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch ...

How will pharma companies react to the administration's efforts? Dr. William Soliman: We’ve seen Pfizer doing a deal with Trump, and I think other companies will follow. If they can come to a ...